Advancing a novel approach to target tumor suppressor p53 for the treatment of cancer and cancer-supportive care

What's New at Aileron

Aileron Therapeutics is a clinical stage company discovering and developing novel medicines for the treatment of cancer and cancer-supportive care by targeting high-value and historically undruggable intracellular targets using a proprietary platform of stabilized cell-permeating peptides.

ALRN-6924 is a first-in-class, stabilized cell-permeating alpha-helical peptide that mimics the p53 tumor suppressor protein to disrupt p53’s interactions with its endogenous inhibitors, MDMX and MDM2.

Latest News

Aileron Therapeutics Reports Third Quarter 2019 Results

Announced positive interim results from its ongoing Phase 2a clinical trial evaluating the combination of ALRN-6924 and Pfizer’s IBRANCE® (palbociclib) for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification Presented new nonclinical data showing ALRN-6924 reduced chemotherapy-related toxicities (“myelopreservation”) in cellular studies and mouse models of cancer without…

Read More
Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th

Nonclinical research showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells without inhibiting the anti-cancer activity of chemotherapy. ALRN-6924 could enable a precision-medicine strategy to prevent the toxic side effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer. WATERTOWN, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) — Aileron…

Read More
Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference

Nonclinical research results show that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells and enhanced the anti-cancer activity of chemotherapy. ALRN-6924 could enable a precision-medicine strategy to prevent the toxic side effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer. WATERTOWN, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE)…

Read More